Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Dostarlimab + TSR-033|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dostarlimab||TSR-042||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||Dostarlimab (TSR-042) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310, PMID: 31847708, PMID: 32213091).|
|TSR-033||TSR033|TSR 033||LAG3 Antibody 10||TSR-033 is a humanized monoclonal antibody that targets LAG3 and inhibits binding of class II MHC molecules, potentially resulting in enhanced anti-tumor immune response, particularly in combination with other agents (PMID: 30587557).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Dostarlimab + TSR-033||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with TSR-033 and Dostarlimab (TSR-042) in combination resulted in increased T-cell number and increased T-cell proliferation in a non-small cell lung cancer cell line xenograft model and had an additive effect on tumor growth inhibition (PMID: 30587557).||30587557|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|